US · TXMD
TherapeuticsMD, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Boca Raton, FL 33431
- Website
- therapeuticsmd.com
Price · as of 2024-12-31
$2.07
Market cap 26.16M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $115.69 | +5,488.89% |
| Intrinsic Value(DCF) | $66.68 | +3,121.26% |
| Graham-Dodd Method(GD) | $1.43 | -31.01% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $350.00 | $810.62 | $0.85 | $0.00 | $0.00 |
| 2011 | $122.50 | $8,671.33 | $92,011.48 | $0.00 | $0.00 |
| 2012 | $170.00 | $207.72 | $118,187.25 | $0.00 | $0.00 |
| 2013 | $389.00 | $224.79 | $2,667,960.90 | $0.00 | $0.00 |
| 2014 | $287.50 | $178.31 | $344,791.76 | $0.00 | $0.00 |
| 2015 | $338.00 | $148.41 | $18,786.34 | $0.00 | $0.00 |
| 2016 | $333.50 | $136.65 | $20.23 | $0.00 | $0.00 |
| 2017 | $273.50 | $111.73 | $15.49 | $0.00 | $87.71 |
| 2018 | $285.00 | $114.00 | $0.00 | $0.00 | $0.00 |
| 2019 | $84.50 | $33.80 | $227.42 | $0.00 | $0.00 |
| 2020 | $79.50 | $31.80 | $496.81 | $0.00 | $0.00 |
| 2021 | $14.50 | $16.05 | $0.00 | $0.00 | $1,812.86 |
| 2022 | $3.88 | $472.73 | $26,111.63 | $65.92 | $31,180.67 |
| 2023 | $2.33 | $66.59 | $6.71 | $0.00 | $84.46 |
| 2024 | $0.87 | $115.69 | $108.41 | $1.43 | $0.00 |
AI valuation
Our deep-learning model estimates TherapeuticsMD, Inc.'s (TXMD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $115.69
- Current price
- $2.07
- AI upside
- +5,488.89%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$66.68
+3,121.26% upside
Graham-Dodd
$1.43
-31.01% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TXMD | TherapeuticsMD, Inc. | $2.07 | 26.16M | +5,489% | +3,121% | -31% | — | -4.34 | 0.37 | 5.70 | -4.07 | — | 0.44 | 100.00% | -270.30% | -123.85% | -8.16% | -15.04% | -5.63% | 0.26 | -501.05 | 1.92 | 1.67 | -0.71 | -7432.00% | 3525.00% | — | 7.30% | 0.14 | 2.34% | 0.00% | 0.00% | 15.57% | -2.55 | 16.60 | 6.90 | -34.01 |
| AYTU | Aytu BioPharma, Inc. | $2.57 | 20.82M | +791% | +627% | — | — | -1.04 | 0.74 | 0.21 | -1.31 | — | -0.61 | 69.04% | -11.79% | -20.43% | -58.10% | -44.62% | -11.16% | 1.21 | -2.11 | 1.26 | 0.98 | 1.72 | -2448.00% | 184.00% | 20082.00% | -36.55% | -0.03 | -29.45% | 0.00% | 0.00% | 31.33% | -0.78 | -1.18 | 0.09 | -3.20 |
| BFRI | Biofrontera Inc. | $0.91 | 10.62M | +16,739% | -59% | — | — | -0.29 | 1.14 | 0.14 | -0.28 | — | 1.15 | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | -203.55% | -0.85 | -169.15% | 0.00% | 0.00% | 99.29% | -0.24 | -0.40 | 0.11 | -7.68 |
| EKSO | Ekso Bionics Holdings, In… | $10.14 | 24.6M | +55% | -60% | — | +814% | -2.12 | 2.75 | 1.94 | -2.68 | -0.27 | 4.87 | 53.48% | -104.12% | -91.37% | -107.62% | -117.46% | -50.02% | 0.29 | -43.13 | 1.63 | 0.98 | -0.15 | 77679.00% | -2860.00% | 2131.00% | -48.31% | -1.37 | -105.67% | 0.91% | -1.90% | 0.91% | -1.97 | -2.19 | 2.05 | -18.15 |
| ERNA | Ernexa Therapeutics Inc. | $0.29 | 2.24M | +35,680% | +510% | — | — | -2.77 | 72.62 | 212.25 | -3.39 | — | -360.15 | 83.51% | -2693.13% | -7652.75% | -2264.31% | -84.37% | -163.74% | 0.40 | -2.32 | 0.80 | 0.74 | 0.03 | -6152.00% | 75588.00% | -2067.00% | -13.12% | -5.39 | -87.22% | 0.00% | 0.00% | 28.59% | -7.81 | -7.56 | 210.46 | -50.59 |
| GELS | Gelteq Limited Ordinary S… | $0.76 | 6.95M | — | +137% | — | — | — | — | — | — | — | — | 100.00% | -3317.65% | -4011.86% | 0.00% | -28.47% | 0.00% | 0.27 | -2.90 | 0.27 | 0.14 | -1.10 | — | — | 40580.00% | — | -0.98 | -31.93% | — | — | — | — | — | — | — |
| MPLT | MapLight Therapeutics, In… | $17.27 | 13.63M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -83.21% | -1592.67% | -67.96% | 0.06 | — | 7.20 | 6.83 | 0.41 | 3955.00% | — | 5168.00% | — | -4.95 | -1528.13% | — | 0.00% | — | — | — | — | — |
| PMN | ProMIS Neurosciences, Inc… | $23.51 | 30.74M | — | — | — | — | 7.09 | 1.19 | — | 2.23 | — | 1.19 | 0.00% | — | — | 27.46% | 589.07% | 17.08% | 0.00 | -219.18 | 8.52 | 6.04 | -4.65 | -10775.00% | — | 15067.00% | -137.99% | -12.25 | 951.55% | 0.00% | 0.00% | 3.52% | -0.38 | -0.23 | — | -3.71 |
| PRPH | ProPhase Labs, Inc. | $0.15 | 710.55K | +15,560% | +1,020% | — | +135,988% | -1.62 | 10.90 | 11.84 | -3.22 | -0.97 | -10.50 | -2.22% | -570.59% | -788.24% | -174.58% | -79.42% | -63.85% | 3.34 | -11.53 | 0.95 | 0.65 | -0.74 | 16633.00% | -8475.00% | 2717.00% | -23.02% | -0.55 | -37.92% | 0.00% | 0.00% | 0.00% | -2.69 | -5.64 | 15.37 | -2.37 |
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
- CEO
- Marlan D. Walker
- Employees
- 1
- Beta
- 0.52
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($66.68 ÷ $2.07) − 1 = +3,121.26% (DCF, example).